{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:14:15Z","timestamp":1788336855069,"version":"build-2803163510"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jdcr.2026.02.038","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T17:01:35Z","timestamp":1771866095000},"page":"39-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["New-onset vitiligo following proprotein convertase subtilisin\/kexin type 9 inhibition with evolocumab: A possible immune-mediated adverse effect"],"prefix":"10.1016","volume":"71","author":[{"given":"Carlos A.","family":"Uma\u00f1a Mejia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Olvera Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Jurado Orozco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose D.","family":"Burgos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jdcr.2026.02.038_bib1","doi-asserted-by":"crossref","first-page":"190","DOI":"10.31083\/j.rcm2505190","article-title":"Review of evolocumab for the reduction of LDL cholesterol and secondary prevention of atherosclerotic cardiovascular disease","volume":"25","author":"Leiter","year":"2024","journal-title":"Rev Cardiovasc Med"},{"issue":"10","key":"10.1016\/j.jdcr.2026.02.038_bib2","article-title":"PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease","volume":"10","author":"Schmidt","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/j.jdcr.2026.02.038_bib3","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.1111\/bcp.15460","article-title":"Adverse event profiles of PCSK9 inhibitors alirocumab and evolocumab: data mining of the FDA adverse event reporting system","volume":"88","author":"Ji","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jdcr.2026.02.038_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.894685","article-title":"Real-world safety of PCSK9 inhibitors: a pharmacovigilance study based on spontaneous reports in FAERS","volume":"13","author":"Feng","year":"2022","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.jdcr.2026.02.038_bib5","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2025.2471451","article-title":"Epidemiology, genetics and management of vitiligo in the USA: an all of us investigation","volume":"36","author":"Gupta","year":"2025","journal-title":"J Dermatolog Treat"},{"issue":"9","key":"10.1016\/j.jdcr.2026.02.038_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0332079","article-title":"Drug-induced vitiligo: a real-world pharmacovigilance analysis of the FAERS database","volume":"20","author":"Shen","year":"2025","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jdcr.2026.02.038_bib7","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jid.2024.07.021","article-title":"PCSK9 inhibitors and the risk of vitiligo: a mendelian randomization study","volume":"145","author":"Kang","year":"2025","journal-title":"J Invest Dermatol"},{"issue":"7839","key":"10.1016\/j.jdcr.2026.02.038_bib8","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41586-020-2911-7","article-title":"Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer","volume":"588","author":"Liu","year":"2020","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.jdcr.2026.02.038_bib9","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.3390\/ijms22063144","article-title":"Pleiotropic effects of PCSK-9 inhibitors","volume":"22","author":"Basiak","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.jdcr.2026.02.038_bib10","article-title":"A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma","volume":"15","author":"Singh","year":"2025","journal-title":"Sci Rep"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626001190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626001190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T07:23:32Z","timestamp":1788333812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512626001190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":10,"alternative-id":["S2352512626001190"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.02.038","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New-onset vitiligo following proprotein convertase subtilisin\/kexin type 9 inhibition with evolocumab: A possible immune-mediated adverse effect","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.02.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}